Atlas Trials

A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults

Clinical trial NCT02298179 · COMPLETED

Trial details

NCT number
NCT02298179
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Respiratory Syncytial Virus (RSV)
Start date
2014-12-19
Primary completion
2017-03-27
Enrollment
288

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.